Literature DB >> 19571805

Systematic evaluation of drug-disease relationships to identify leads for novel drug uses.

A P Chiang1, A J Butte.   

Abstract

Drug repositioning refers to the discovery of alternative uses for drugs--uses that are different from that for which the drugs were originally intended. One challenge in this effort lies in choosing the indication for which a drug of interest could be prospectively tested. We systematically evaluated a drug treatment-based view of diseases in order to address this challenge. Suggestions for novel drug uses were generated using a "guilt by association" approach. When compared with a control group of drug uses, the suggested novel drug uses generated by this approach were significantly enriched with respect to previous and ongoing clinical trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19571805      PMCID: PMC2836384          DOI: 10.1038/clpt.2009.103

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

1.  New drug development in the United States from 1963 to 1999.

Authors:  J A Dimasi
Journal:  Clin Pharmacol Ther       Date:  2001-05       Impact factor: 6.875

2.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

Review 3.  Drug repositioning: identifying and developing new uses for existing drugs.

Authors:  Ted T Ashburn; Karl B Thor
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

4.  Exploring the geometry of treatment networks.

Authors:  Georgia Salanti; Fotini K Kavvoura; John P A Ioannidis
Journal:  Ann Intern Med       Date:  2008-04-01       Impact factor: 25.391

5.  Drug-target network.

Authors:  Muhammed A Yildirim; Kwang-Il Goh; Michael E Cusick; Albert-László Barabási; Marc Vidal
Journal:  Nat Biotechnol       Date:  2007-10       Impact factor: 54.908

6.  Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.

Authors:  V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

7.  Antitumor activity of thalidomide in refractory multiple myeloma.

Authors:  S Singhal; J Mehta; R Desikan; D Ayers; P Roberson; P Eddlemon; N Munshi; E Anaissie; C Wilson; M Dhodapkar; J Zeddis; B Barlogie
Journal:  N Engl J Med       Date:  1999-11-18       Impact factor: 91.245

8.  Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.

Authors:  S L Soignet; P Maslak; Z G Wang; S Jhanwar; E Calleja; L J Dardashti; D Corso; A DeBlasio; J Gabrilove; D A Scheinberg; P P Pandolfi; R P Warrell
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

9.  Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.

Authors:  Catherine M Shachaf; Omar D Perez; Sawsan Youssef; Alice C Fan; Sailaja Elchuri; Matthew J Goldstein; Amy E Shirer; Orr Sharpe; Joy Chen; Dennis J Mitchell; Maria Chang; Garry P Nolan; Lawrence Steinman; Dean W Felsher
Journal:  Blood       Date:  2007-07-10       Impact factor: 22.113

10.  Statin-induced inhibition of 3-hydroxy-3-methyl glutaryl coenzyme a reductase sensitizes human osteosarcoma cells to anticancer drugs.

Authors:  Olivia Fromigué; Zahia Hamidouche; Pierre J Marie
Journal:  J Pharmacol Exp Ther       Date:  2008-02-05       Impact factor: 4.030

View more
  74 in total

1.  Drug repositioning using disease associated biological processes and network analysis of drug targets.

Authors:  Sachin Mathur; Deendayal Dinakarpandian
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

2.  Drug discovery in a multidimensional world: systems, patterns, and networks.

Authors:  Joel T Dudley; Eric Schadt; Marina Sirota; Atul J Butte; Euan Ashley
Journal:  J Cardiovasc Transl Res       Date:  2010-07-31       Impact factor: 4.132

3.  Towards drug repositioning: a unified computational framework for integrating multiple aspects of drug similarity and disease similarity.

Authors:  Ping Zhang; Fei Wang; Jianying Hu
Journal:  AMIA Annu Symp Proc       Date:  2014-11-14

4.  PhenoPredict: A disease phenome-wide drug repositioning approach towards schizophrenia drug discovery.

Authors:  Rong Xu; QuanQiu Wang
Journal:  J Biomed Inform       Date:  2015-07-04       Impact factor: 6.317

5.  An integrated network platform for contextual prioritization of drugs and pathways.

Authors:  Aldo Segura-Cabrera; Navneet Singh; Kakajan Komurov
Journal:  Mol Biosyst       Date:  2015-11

Review 6.  Exploiting drug-disease relationships for computational drug repositioning.

Authors:  Joel T Dudley; Tarangini Deshpande; Atul J Butte
Journal:  Brief Bioinform       Date:  2011-06-20       Impact factor: 11.622

7.  Retrospective analysis of health claims to evaluate pharmacotherapies with potential for repurposing: Association of bupropion and stimulant use disorder remission.

Authors:  Emily R Hankosky; Heather M Bush; Linda P Dwoskin; Daniel R Harris; Darren W Henderson; Guo-Qiang Zhang; Patricia R Freeman; Jeffery C Talbert
Journal:  AMIA Annu Symp Proc       Date:  2018-12-05

Review 8.  The emerging paradigm of network medicine in the study of human disease.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  Circ Res       Date:  2012-07-20       Impact factor: 17.367

9.  Drug repositioning by integrating target information through a heterogeneous network model.

Authors:  Wenhui Wang; Sen Yang; Xiang Zhang; Jing Li
Journal:  Bioinformatics       Date:  2014-06-27       Impact factor: 6.937

10.  Drug target predictions based on heterogeneous graph inference.

Authors:  Wenhui Wang; Sen Yang; Jing Li
Journal:  Pac Symp Biocomput       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.